Dr. Kottler sat down with Diagnostic Imaging at RSNA 2023 to discuss AI imaging milestones and the potential impact of AI on workflows in radiology.
Artificial intelligence (AI) is of course one of, if not the hottest topic at this year's RSNA annual meeting, but how is all of the hype translating to clinical practice?
As exciting as new technology can be, actually using that technology requires a great deal of effort, especially for larger institutions that are faced with training dozens of radiology staff.
User education is a key component to adoption and uptake, according to Nina Kottler, MD, MS, associate chief medical officer of clinical artificial intelligence at Radiology Partners. Dr. Kottler spoke with Diagnostic Imaging at RSNA 2023, where she reflected on Radiology Partners hitting (and recently surpassing) an impressive milestone: utilizing clinical AI in more than 20 million patient exams. None of that would be possible without purposeful training programs to make sure that radiology end-users are comfortable with the new technology and understand the key benefits of use.
Dr. Kottler, who is also an associate fellow at Stanford University's Center for Artificial Intelligence in Medicine & Imaging (AIMI), also spoke about what she has observed in terms of the affect that AI is having on radiology workflows.
Watch the interview below for additional insights on AI.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.